Aytu BioPharma, Inc.

No trades
See on Supercharts

AYTU fundamentals

Aytu BioPharma, Inc. financial statements, including revenue, expenses, profit, and loss

The total revenue of AYTU for the last quarter is 22.73M USD, and it's 13.49% lower compared to the previous quarter. The net income of Q3 23 is -7.20M USD.

Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: USD
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Total revenueYoY growth
Cost of goods sold
Gross profitYoY growth
Operating expenses (excl. COGS)
Operating incomeYoY growth
Non-operating income, total
Pretax incomeYoY growth
Equity in earnings
Non-controlling/minority interest
After tax other income/expense
Net income before discontinued operations
Discontinued operations
Net incomeYoY growth
Dilution adjustment
Preferred dividends
Diluted net income available to common stockholders
Basic earnings per share (Basic EPS)YoY growth
Diluted earnings per share (Diluted EPS)YoY growth
Average basic shares outstanding
Diluted shares outstanding
EBITDAYoY growth
EBITYoY growth
Total operating expenses